BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kanda M, Sugimoto H, Kodera Y. Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World J Gastroenterol 2015; 21(37): 10584-10597 [PMID: 26457018 DOI: 10.3748/wjg.v21.i37.10584] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 46] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Wang Y, Sun M, Liu J, Liu Y, Jiang C, Zhu H, Wang W, Wang Y. FIBCD1 overexpression predicts poor prognosis in patients with hepatocellular carcinoma. Oncol Lett 2020;19:795-804. [PMID: 31897196 DOI: 10.3892/ol.2019.11183] [Reference Citation Analysis]
2 Liu A, Wu Q, Peng D, Ares I, Anadón A, Lopez-Torres B, Martínez-Larrañaga MR, Wang X, Martínez MA. A novel strategy for the diagnosis, prognosis, treatment, and chemoresistance of hepatocellular carcinoma: DNA methylation. Med Res Rev 2020;40:1973-2018. [PMID: 32525219 DOI: 10.1002/med.21696] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
3 Huang XY, Huang ZL, Xu YH, Zheng Q, Chen Z, Song W, Zhou J, Tang ZY, Huang XY. Comprehensive circular RNA profiling reveals the regulatory role of the circRNA-100338/miR-141-3p pathway in hepatitis B-related hepatocellular carcinoma. Sci Rep. 2017;7:5428. [PMID: 28710406 DOI: 10.1038/s41598-017-05432-8] [Cited by in Crossref: 119] [Cited by in F6Publishing: 128] [Article Influence: 29.8] [Reference Citation Analysis]
4 Pu M, Wang J, Huang Q, Zhao G, Xia C, Shang R, Zhang Z, Bian Z, Yang X, Tao K. High MRPS23 expression contributes to hepatocellular carcinoma proliferation and indicates poor survival outcomes. Tumour Biol 2017;39:101042831770912. [DOI: 10.1177/1010428317709127] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
5 Song C, Liu Y, Xu L, Wen J, Jiang D, Chen J, Zhai X, Hu Z, Liu L, Liu J. Hepatitis B virus mutations, expression quantitative trait loci for PTPN12, and their interactions in hepatocellular carcinoma. Cancer Med 2016;5:1687-93. [PMID: 27075395 DOI: 10.1002/cam4.712] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
6 Cheng N, Wu J, Yin M, Xu J, Wang Y, Chen X, Nie Z, Yin J. LncRNA CASC11 promotes cancer cell proliferation in hepatocellular carcinoma by inhibiting miRNA-188-5p. Biosci Rep 2019;39:BSR20190251. [PMID: 30910841 DOI: 10.1042/BSR20190251] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
7 Ye Z, Chen X, Chen X. ARK5 promotes invasion and migration in hepatocellular carcinoma cells by regulating epithelial-mesenchymal transition. Oncol Lett 2018;15:1511-6. [PMID: 29434843 DOI: 10.3892/ol.2017.7453] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
8 Li BH, Wang Y, Wang CY, Zhao MJ, Deng T, Ren XQ. Up-Regulation of Phosphatase in Regenerating Liver-3 (PRL-3) Contributes to Malignant Progression of Hepatocellular Carcinoma by Activating Phosphatase and Tensin Homolog Deleted on Chromosome Ten (PTEN)/Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway. Med Sci Monit 2018;24:8105-14. [PMID: 30418964 DOI: 10.12659/MSM.913307] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Zhang JH, Jiao LY, Li TJ, Zhu YY, Zhou JW, Tian J. GSK-3β suppresses HCC cell dissociation in vitro by upregulating epithelial junction proteins and inhibiting Wnt/β-catenin signaling pathway. J Cancer 2017;8:1598-608. [PMID: 28775779 DOI: 10.7150/jca.18744] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
10 Amicone L, Marchetti A. Microenvironment and tumor cells: two targets for new molecular therapies of hepatocellular carcinoma. Transl Gastroenterol Hepatol 2018;3:24. [PMID: 29971255 DOI: 10.21037/tgh.2018.04.05] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
11 Choiniere J, Wu J, Wang L. Pyruvate Dehydrogenase Kinase 4 Deficiency Results in Expedited Cellular Proliferation through E2F1-Mediated Increase of Cyclins. Mol Pharmacol 2017;91:189-96. [PMID: 28003426 DOI: 10.1124/mol.116.106757] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
12 López-Álvarez GS, Wojdacz TK, García-Cuellar CM, Monroy-Ramírez HC, Rodríguez-Segura MA, Pacheco-Rivera RA, Valencia-Antúnez CA, Cervantes-Anaya N, Soto-Reyes E, Vásquez-Garzón VR, Sánchez-Pérez Y, Villa-Treviño S. Gene silencing of Nox4 by CpG island methylation during hepatocarcinogenesis in rats. Biol Open 2017;6:59-70. [PMID: 27895046 DOI: 10.1242/bio.020370] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
13 Kanda M, Murotani K, Sugimoto H, Miwa T, Umeda S, Suenaga M, Hayashi M, Hattori N, Tanaka C, Kobayashi D, Yamada S, Fujiwara M, Kodera Y. An integrated multigene expression panel to predict long-term survival after curative hepatectomy in patients with hepatocellular carcinoma. Oncotarget 2017;8:71070-9. [PMID: 29050343 DOI: 10.18632/oncotarget.20369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
14 Kanda M, Kodera Y. Molecular mechanisms of peritoneal dissemination in gastric cancer. World J Gastroenterol 2016; 22(30): 6829-6840 [PMID: 27570420 DOI: 10.3748/wjg.v22.i30.6829] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 60] [Article Influence: 13.6] [Reference Citation Analysis]
15 Nan YL, Hu YL, Liu ZK, Duan FF, Xu Y, Li S, Li T, Chen DF, Zeng XY. Relationships between cell cycle pathway gene polymorphisms and risk of hepatocellular carcinoma. World J Gastroenterol 2016; 22(24): 5558-5567 [PMID: 27350734 DOI: 10.3748/wjg.v22.i24.5558] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
16 Wu M, Xia X, Hu J, Fowlkes NW, Li S. WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression. Nat Commun 2021;12:3500. [PMID: 34108491 DOI: 10.1038/s41467-021-23864-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Guo C, Zhou J, Ma B, Wang R, Ge Y, Wang Z, Ji B, Wang W, Zhang J, Wang Z. A Somatic Mutation-Derived LncRNA Signature of Genomic Instability Predicts Prognosis for Patients With Liver Cancer. Front Surg 2021;8:724792. [PMID: 34504866 DOI: 10.3389/fsurg.2021.724792] [Reference Citation Analysis]
18 Ni FB, Lin Z, Fan XH, Shi KQ, Ao JY, Wang XD, Chen RC. A novel genomic-clinicopathologic nomogram to improve prognosis prediction of hepatocellular carcinoma. Clin Chim Acta 2020;504:88-97. [PMID: 32032609 DOI: 10.1016/j.cca.2020.02.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
19 Rao CV, Asch AS, Yamada HY. Frequently mutated genes/pathways and genomic instability as prevention targets in liver cancer. Carcinogenesis. 2017;38:2-11. [PMID: 27838634 DOI: 10.1093/carcin/bgw118] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 11.2] [Reference Citation Analysis]
20 Huang WT, Chen ZX, He RQ, Wu YZ, Yin SY, Liang XN, Chen G, Yang H, Peng ZG, Yang LH. Clinicopathological role of miR-30a-5p in hepatocellular carcinoma tissues and prediction of its function with bioinformatics analysis. Onco Targets Ther 2016;9:5061-71. [PMID: 27574447 DOI: 10.2147/OTT.S111431] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
21 Liu D, Zhou G, Shi H, Chen B, Sun X, Zhang X. Downregulation of Transmembrane protein 40 by miR-138-5p Suppresses Cell Proliferation and Mobility in Clear Cell Renal Cell Carcinoma. Iran J Biotechnol 2020;18:e2270. [PMID: 32884956 DOI: 10.30498/IJB.2019.85193] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Qing X, Xu W, Zong J, Du X, Peng H, Zhang Y. Emerging treatment modalities for systemic therapy in hepatocellular carcinoma. Biomark Res 2021;9:64. [PMID: 34419152 DOI: 10.1186/s40364-021-00319-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Laube B, Michaelsen S, Meischner V, Hartwig A, Epe B, Schwarz M. Classification or non-classification of substances with positive tumor findings in animal studies: Guidance by the German MAK commission. Regul Toxicol Pharmacol 2019;108:104444. [PMID: 31433998 DOI: 10.1016/j.yrtph.2019.104444] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Yuan W, Li F. Roles of microRNA-186 and vascular endothelial growth factor in hepatocellular carcinoma complicated with portal vein tumor thrombus. Exp Ther Med 2020;20:3860-7. [PMID: 32855736 DOI: 10.3892/etm.2020.9092] [Reference Citation Analysis]
25 Saber MA, MM AbdelHafiz S, Khorshed FE, Aboushousha TS, Hamdy HE, Seleem MI, Soliman AH. Differential Expression of Glypican-3 and Insulin–Like Growth Factor-II mRNAs and Alpha-Fetoprotein and Ki-67 Markers in HCV Related Hepatocellular Carcinomas In Egyptian Patients. Asian Pac J Cancer Prev 2017;18:121-7. [PMID: 28240019 DOI: 10.22034/APJCP.2017.18.1.121] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
26 Shimizu D, Kanda M, Sugimoto H, Shibata M, Tanaka H, Takami H, Iwata N, Hayashi M, Tanaka C, Kobayashi D, Yamada S, Nakayama G, Koike M, Fujiwara M, Fujii T, Kodera Y. The protein arginine methyltransferase 5 promotes malignant phenotype of hepatocellular carcinoma cells and is associated with adverse patient outcomes after curative hepatectomy. Int J Oncol 2017;50:381-6. [PMID: 28101581 DOI: 10.3892/ijo.2017.3833] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
27 Wang J, Wu S, Huang T. Expression and role of VEGFA and miR-381 in portal vein tumor thrombi in patients with hepatocellular carcinoma. Exp Ther Med 2018;15:5450-6. [PMID: 29904424 DOI: 10.3892/etm.2018.6129] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
28 Peng L, Yuan XQ, Zhang CY, Peng JY, Zhang YQ, Pan X, Li GC. The emergence of long non-coding RNAs in hepatocellular carcinoma: an update. J Cancer. 2018;9:2549-2558. [PMID: 30026854 DOI: 10.7150/jca.24560] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
29 Tang W, Yang L, Yang T, Liu M, Zhou Y, Lin J, Wang K, Ding C. INPP4B inhibits cell proliferation, invasion and chemoresistance in human hepatocellular carcinoma. Onco Targets Ther 2019;12:3491-507. [PMID: 31123408 DOI: 10.2147/OTT.S196832] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Wu B, Liang X, Jing H, Han X, Sun Y, Guo C, Liu Y, Cheng W. Effect of NET-1 siRNA conjugated sub-micron bubble complex combined with low-frequency ultrasound exposure in gene transfection. Oncotarget 2018;9:4150-60. [PMID: 29423111 DOI: 10.18632/oncotarget.23646] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Liu X, Hu X, Kuang Y, Yan P, Li L, Li C, Tao Q, Cai X. BCLB, methylated in hepatocellular carcinoma, is a starvation stress sensor that induces apoptosis and autophagy through the AMPK-mTOR signaling cascade. Cancer Lett 2017;395:63-71. [PMID: 28259820 DOI: 10.1016/j.canlet.2017.02.030] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
32 Cao L, Zhang L, Zhao X, Zhang Y. A Hybrid Chalcone Combining the Trimethoxyphenyl and Isatinyl Groups Targets Multiple Oncogenic Proteins and Pathways in Hepatocellular Carcinoma Cells. PLoS One 2016;11:e0161025. [PMID: 27525972 DOI: 10.1371/journal.pone.0161025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
33 Umeda S, Kanda M, Kodera Y. Recent advances in molecular biomarkers for patients with hepatocellular carcinoma. Expert Rev Mol Diagn 2019;19:725-38. [PMID: 31248309 DOI: 10.1080/14737159.2019.1638254] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
34 Zhang Y, Liu X, Liu L, Li J, Hu Q, Sun R. Expression and Prognostic Significance of m6A-Related Genes in Lung Adenocarcinoma. Med Sci Monit 2020;26:e919644. [PMID: 32086933 DOI: 10.12659/MSM.919644] [Cited by in Crossref: 10] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
35 Wu Y, Zhang Y, Qin X, Geng H, Zuo D, Zhao Q. PI3K/AKT/mTOR pathway-related long non-coding RNAs: roles and mechanisms in hepatocellular carcinoma. Pharmacol Res 2020;160:105195. [PMID: 32916254 DOI: 10.1016/j.phrs.2020.105195] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
36 Panera N, Crudele A, Romito I, Gnani D, Alisi A. Focal Adhesion Kinase: Insight into Molecular Roles and Functions in Hepatocellular Carcinoma. Int J Mol Sci 2017;18:E99. [PMID: 28067792 DOI: 10.3390/ijms18010099] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 8.5] [Reference Citation Analysis]
37 Umeda S, Kanda M, Sugimoto H, Tanaka H, Hayashi M, Yamada S, Fujii T, Takami H, Niwa Y, Iwata N, Tanaka C, Kobayashi D, Fujiwara M, Kodera Y. Downregulation of GPR155 as a prognostic factor after curative resection of hepatocellular carcinoma. BMC Cancer 2017;17:610. [PMID: 28863781 DOI: 10.1186/s12885-017-3629-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
38 Umetsu S, Mizukami H, Saito T, Uchida C, Igawa A, Kudo K, Itabashi C, Osonoi S, Danyang G, Sasaki T, Yagihashi S, Hakamada K. Diabetes, an independent poor prognostic factor of non-B non-C hepatocellular carcinoma, correlates with dihydropyrimidinase-like 3 promoter methylation. Sci Rep 2020;10:1156. [PMID: 31980687 DOI: 10.1038/s41598-020-57883-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Kanda M, Shimizu D, Tanaka H, Shibata M, Iwata N, Hayashi M, Kobayashi D, Tanaka C, Yamada S, Fujii T. Metastatic pathway-specific transcriptome analysis identifies MFSD4 as a putative tumor suppressor and biomarker for hepatic metastasis in patients with gastric cancer. Oncotarget. 2016;7:13667-13679. [PMID: 26872374 DOI: 10.18632/oncotarget.7269] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 9.3] [Reference Citation Analysis]
40 Tang JC, Feng YL, Guo T, Xie AY, Cai XJ. Circulating tumor DNA in hepatocellular carcinoma: Trends and challenges. Cell Biosci. 2016;6:32. [PMID: 27182434 DOI: 10.1186/s13578-016-0100-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
41 Tang Q, Wang Q, Zhang Q, Lin SY, Zhu Y, Yang X, Guo AY. Gene expression, regulation of DEN and HBx induced HCC mice models and comparisons of tumor, para-tumor and normal tissues. BMC Cancer 2017;17:862. [PMID: 29254483 DOI: 10.1186/s12885-017-3860-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
42 Liu X, Chen X, Xiao M, Zhu Y, Gong R, Liu J, Zeng Q, Xu C, Chen X, Wang F, Cao K. RANBP2 Activates O-GlcNAcylation through Inducing CEBPα-Dependent OGA Downregulation to Promote Hepatocellular Carcinoma Malignant Phenotypes. Cancers (Basel) 2021;13:3475. [PMID: 34298689 DOI: 10.3390/cancers13143475] [Reference Citation Analysis]
43 Jia YY, Zhao JY, Li BL, Gao K, Song Y, Liu MY, Yang XJ, Xue Y, Wen AD, Shi L. miR-592/WSB1/HIF-1α axis inhibits glycolytic metabolism to decrease hepatocellular carcinoma growth. Oncotarget 2016;7:35257-69. [PMID: 27153552 DOI: 10.18632/oncotarget.9135] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 7.7] [Reference Citation Analysis]
44 Li H, Chen H, Wang H, Dong Y, Yin M, Zhang L, Wei J. MicroRNA-374a Promotes Hepatocellular Carcinoma Cell Proliferation by Targeting Mitogen-Inducible Gene 6 (MIG-6). Oncol Res 2018;26:557-63. [PMID: 28734040 DOI: 10.3727/096504017X15000784459799] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
45 Niu L, Liu L, Yang S, Ren J, Lai PBS, Chen GG. New insights into sorafenib resistance in hepatocellular carcinoma: Responsible mechanisms and promising strategies. Biochim Biophys Acta Rev Cancer. 2017;1868:564-570. [PMID: 29054475 DOI: 10.1016/j.bbcan.2017.10.002] [Cited by in Crossref: 72] [Cited by in F6Publishing: 87] [Article Influence: 18.0] [Reference Citation Analysis]
46 Huang JL, Wang XK, Liao XW, Han CY, Yu TD, Huang KT, Yang CK, Liu XG, Yu L, Zhu GZ, Su H, Qin W, Han QF, Liu ZQ, Zhou X, Liu JQ, Ye XP, Peng T. SOX4 as biomarker in hepatitis B virus-associated hepatocellular carcinoma. J Cancer 2021;12:3486-500. [PMID: 33995626 DOI: 10.7150/jca.46579] [Reference Citation Analysis]